Yet, the clinical utility of established biomarkers is limited in particular by their lack of sensitivity for the early detection of HF. Metabolomics of plasma samples was performed by both untargeted and targeted GC-MS and LC-MS/MS. In the initial single center identification phase metabolites were nominated for multimarker panels and their performance was verified in an independent validation cohort from three clinical centers (in total >800 HF patients and >330 healthy controls). The metabolite multimarkers not only showed a similar diagnostic performance compared to NT-proBNP, but also demonstrated a significant added diagnostic value when combining with NT-proBNP for several HF subgroups. We conclude that metabolomic biomarkers may be useful in the early detection of HF.
New Metabolomics Biomarker for Heart Failure
Video Apr 27, 2015
Behind the Science, S3 Ep 1: Exploring new dimensions in chromatography with Claude MalletVideo
To kick off season 3 of Behind the Science, our host Jen Fournier meets Claude Mallet of Waters at his new multi-dimensional chromatography lab to break down the myths of 2D LC, also known as LCxLC.WATCH NOW
Claisse® LeDoser 12™ Instrument - Just-in-time weighing for optimal precision and repeatability!Video
LeDoser-12 is a robust instrument that does not get tired or distracted; it can work in harsh work conditions and always provides the same repeatability.WATCH NOW